PedAM
Pediatric Disease Annotations & Medicines
| hemolytic-uremic syndrome | ||||
| Disease ID | 175 |
|---|---|
| Disease | hemolytic-uremic syndrome |
| Manually Symptom | UMLS | Name(Total Manually Symptoms:17) C2364133 | infection C1963084 | colitis C0577708 | escherichia coli urinary tract infection C0521610 | emphysematous cholecystitis C0476273 | respiratory distress C0342723 | cobalamin c disease C0238106 | clostridium difficile colitis C0151565 | hemorrhagic colitis C0038454 | strokes C0038454 | stroke C0034888 | rectal prolapse C0024588 | malignant hypertension C0022660 | acute renal failure C0014836 | escherichia coli infections C0014836 | escherichia coli infection C0014335 | enteritis C0013384 | abnormal movements |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:9) C0035078 | renal failure | 9 C0009319 | colitis | 5 C0022660 | acute renal failure | 4 C0151594 | bloody diarrhea | 3 C0151565 | hemorrhagic colitis | 3 C0009450 | infection | 2 C0017662 | membranoproliferative glomerulonephritis | 1 C0022656 | renal cortical necrosis | 1 C0398777 | complement factor h deficiency | 1 |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:1) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
| rs121913060 | 17229916 | 3075 | CFH | umls:C0019061 | BeFree | Hemolytic uremic syndrome: a factor H mutation (E1172Stop) causes defective complement control at the surface of endothelial cells. | 0.060099239 | 2007 | CFH | 1 | 196747131 | G | T |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:20) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0019061 | ampicillin | D000667 | 69-53-4 | hemolytic-uremic syndrome | MESH:D006463 | marker/mechanism | 2306432 | ||
| C0019061 | bleomycin | D001761 | 11056-06-7 | hemolytic-uremic syndrome | MESH:D006463 | marker/mechanism | 10435899 | ||
| C0019061 | ciprofloxacin | D002939 | 85721-33-1 | hemolytic-uremic syndrome | MESH:D006463 | marker/mechanism | 12022900 | ||
| C0019061 | cyclosporine | D016572 | 59865-13-3 | hemolytic-uremic syndrome | MESH:D006463 | marker/mechanism | 11140243 | ||
| C0019061 | cisplatin | D002945 | 15663-27-1 | hemolytic-uremic syndrome | MESH:D006463 | marker/mechanism | 10435899 | ||
| C0019061 | cisplatin | D002945 | 15663-27-1 | hemolytic-uremic syndrome | MESH:D006463 | therapeutic | 1699855 | ||
| C0019061 | epirubicin | D015251 | 56420-45-2 | hemolytic-uremic syndrome | MESH:D006463 | marker/mechanism | 9572663 | ||
| C0019061 | erythromycin | D004917 | 114-07-8 | hemolytic-uremic syndrome | MESH:D006463 | marker/mechanism | 20813025 | ||
| C0019061 | everolimus | D000068338 | - | hemolytic-uremic syndrome | MESH:D006463 | marker/mechanism | 17951952 | ||
| C0019061 | fluorouracil | D005472 | 51-21-8 | hemolytic-uremic syndrome | MESH:D006463 | marker/mechanism | 12119460 | ||
| C0019061 | leucovorin | D002955 | 1958/5/9 | hemolytic-uremic syndrome | MESH:D006463 | marker/mechanism | 12119460 | ||
| C0019061 | gemcitabine | C056507 | 103882-84-4 | hemolytic-uremic syndrome | MESH:D006463 | marker/mechanism | 10528696 | ||
| C0019061 | mitomycin | D016685 | 1950/7/7 | hemolytic-uremic syndrome | MESH:D006463 | marker/mechanism | 10178695 | ||
| C0019061 | quinine | D011803 | 130-95-0 | hemolytic-uremic syndrome | MESH:D006463 | marker/mechanism | 10923967 | ||
| C0019061 | sirolimus | D020123 | 53123-88-9 | hemolytic-uremic syndrome | MESH:D006463 | marker/mechanism | 15625544 | ||
| C0019061 | tacrolimus | D016559 | 109581-93-3 | hemolytic-uremic syndrome | MESH:D006463 | marker/mechanism | 10328486 | ||
| C0019061 | ticlopidine | D013988 | 55142-85-3 | hemolytic-uremic syndrome | MESH:D006463 | marker/mechanism | 11604563 | ||
| C0019061 | vinblastine | D014747 | 865-21-4 | hemolytic-uremic syndrome | MESH:D006463 | marker/mechanism | 7679450 | ||
| C0019061 | vincristine | D014750 | - | hemolytic-uremic syndrome | MESH:D006463 | marker/mechanism | 11037870 | ||
| C0019061 | vincristine | D014750 | - | hemolytic-uremic syndrome | MESH:D006463 | therapeutic | 6846975 | ||
FDA approved drug and dosage information(Total Drugs:5) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D006463 | cipro | ciprofloxacin | 400MG/40ML (10MG/ML) | INJECTABLE;INJECTION | Discontinued | None | Yes | No |
| MESH:D006463 | cipro | ciprofloxacin | 250MG/5ML | FOR SUSPENSION;ORAL | Prescription | AB | Yes | No |
| MESH:D006463 | rapamune | sirolimus | 1MG/ML | SOLUTION;ORAL | Prescription | None | Yes | Yes |
| MESH:D006463 | rapamune | sirolimus | 1MG | TABLET;ORAL | Prescription | AB | Yes | No |
| MESH:D006463 | afinitor | everolimus | 5MG | TABLET;ORAL | Prescription | None | Yes | No |
FDA labeling changes(Total Drugs:5) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D006463 | 03/25/2004 | cipro | ciprofloxacin | Complicated UTI and pyelonephritis | Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively | Labeling | B | - | - | - | Bayer | 12/18/2003 | FALSE' |
| MESH:D006463 | 03/25/2004 | cipro | ciprofloxacin | Complicated UTI and pyelonephritis | Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively | Labeling | B | - | - | - | Bayer | 12/18/2003 | FALSE' |
| MESH:D006463 | 11/3/2005 | rapamune | sirolimus | Prophylaxis of organ rejection in patients undergoing renal transplants | Safety and efficacy established in children 13 years or older judged to be at low to moderate immunologic risk Safety was assessed in a controlled clinical trial in pediatric ( | Labeling | B | - | - | - | Wyeth | 11/17/2004 | FALSE' |
| MESH:D006463 | 11/3/2005 | rapamune | sirolimus | Prophylaxis of organ rejection in patients undergoing renal transplants | Safety and efficacy established in children 13 years or older judged to be at low to moderate immunologic risk Safety was assessed in a controlled clinical trial in pediatric ( | Labeling | B | - | - | - | Wyeth | 11/17/2004 | FALSE' |
| MESH:D006463 | 10/29/2010 | afinitor | everolimus | Treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis | Approved for treatment of patients with SEGA associated with TS An open-label, single-arm safety and efficacy trial was conducted in 28 patients 3-34 years with SEGA associated with TS Afinitor has not been studied in patients with SEGA < 3 years of ageMost common adverse reactions (incidence e30%) were stomatitis, upper respiratory tract infection, sinusitis, otitis media, and pyrexiaDose reduction and/or treatment interruption may be needed to manage adverse drug reactions Information on starting dose, therapeutic drug monitoring, clinical trial, and adverse reactions New indication | Labeling | B | - | - | - | Novartis | - | FALSE' |